drugset / Trial / NCT07391839

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

NCT07391839 ↗

Phase 1 Recruiting 40 enrolled Suzhou Mednovo Yi Medical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Timeline

Start
2025-08-04
Primary completion
2026-08-30
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MDN-001 Unknown — —